Sanofi-Astrazeneca preventive RSV drug recommended for approval by CHMP
The EU’s authority in charge of reviewing drug applications before final approval has given a positive opinion on the world’s first, and only, preventive treatment for RSV in infants.
by christopher due karlsson, translated by daniel pedersen
On Friday, the European Medicines Agency’s (EMA) special committee, the CHMP, sent a preventive treatment for respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants one step closer to European market authorization.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to submit RSV vaccine for FDA approval in fall
For subscribers
Pfizer initiates phase III of influenza vaccine candidate
For subscribers
